Clastogenic activity of 2-chlorodeoxyadenosine in mammalian somatic cells

Genetics and Molecular Biology

Volumn 28, Issue 2, 2005, Pages 339-344

  Antonucci, Gilmara Ausech ^a   Takahashi, Catarina Satie ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

2 CdA; Cell cycle; Chromosomal aberrations; Human lymphocytes; SCE

Indexed keywords

CLADRIBINE;

ADULT; ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CHROMOSOME ABERRATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MITOSIS; MOUSE; NONHUMAN; SISTER CHROMATID EXCHANGE; SOMATIC CELL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ANIMALIA; MAMMALIA;

EID: 30644457195     PISSN: 14154757     EISSN: 16784685     Source Type: Journal    
DOI: 10.1590/S1415-47572005000200027     Document Type: Article

References (35)

1. Andreassen PR, Lohez OD and Margolis RL (2003) G2 and spindle the assembly checkpoint adaptation, and tetraploidy arrest: Implications for intrinsic and chemically induced genomic instability. Mutat Res 532:245-53.
2. Aydemir N and Bilaloglu R (2003) Genotoxicity of two anticancer drugs, gemcitabine and topotecan, in mouse bone marrow in vivo. Mutat Res 537:43-51.
3. Baltz JK and Montello MJ (1993) Cladribine for the treatment of hematologic malignancies. Clinical Pharmacy 12:805-813.
4. Caldecott KW (2004) DNA single-strand breaks and neurodegeneration. DNA Repair (Amst) 3:875-82.
5. Carson DA, Wasson DB, Taetle R and Yu A (1983) Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes, Blood 62:737-743.
6. Degrassi F, De Salvia R, Tanzarella C and Palitti F (1989) Induction of chromosomal aberrations and SCE by camptothecin, an inhibitor of mammalian topoisomerase I. Mutat Res 211:125-130.
7. Evans HJ and Scott D (1964) Influence of DNA synthesis on the production of chromatid aberrations by X-rays and maleic hydrazide in Vicia faba Genetics 49:17-38.
8. Ford CE and Hamerton JL (1956) A colchicine hypotonic citrate squash sequence for mammalian chromosomes. Technol 3:247-251.
9. Galmarini CM, Mackey JR and Dumontet C (2001) Nucleoside analogues: Mechanisms of drug resistance and reversal strategies. Leukemia 15:875-890.
10. Gandhi V, Huang P, Chapman AJ, Chen F and Plunkett W (1997) Incorporation of fludarabine and 1-beta-D-arabinofuranosylcytosine 5'triphosphates by DNA polymerase alpha: Affinity, interaction and consequences. Clin Cancer Res 3:1347-1355.
11. Genini D, Adachi S, Chao Q, Rose DW, Carrera CJ, Cottam HB, Carson DA and Leoni LM (2000) Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood 96:3537-3543.
12. Huggett AC, Schilter B, Roberfroid M, Antignac E and Koeman JH (1996) Comparative methods of toxicity testing. Food Chem Toxicol 34:183-92.
13. Korenberg JR and Freedlender EF (1974) Giemsa technique for the detection of sister chromatid exchanges. Chromosoma 48:355-360.
14. Laurencet FM, Zulian GB, Guetty-Alberto M, Iten PA, Betticher DC and Alberto P (1999) Cladribine with cyclophosphamide and prednisone in management of low-grade lymphoproliferative malignancies. Br J Haematol 79:1215-1219.
15. Legator MS and Ward Jr JB (1991) Use of in vivo genetic toxicity data for risk assessment. Mutat Res 250:457-465.
16. Liliemark J and Juliusson G (1994) 2-Chloro-2'-deoxyadenosine-clinical, biochemical and pharmacokinetic considerations. Arch Immunol Ther Exp (Warsz) 42:7-10.
17. Mathew S, Lorsbach RB, Shearer P, Sandlund JT and Raimondi SC (2000) Double minute chromosomes and c-MYC amplification in a child with secondary myelodysplastic syndrome after treatment for acute lymphoblastic leukemia. Leukemia 14:1314-5.
18. Moore RC and Bender MA (1993) Time sequence of events leading to chromosomal aberration formation. Environ Mol Mutagen 22:208-213.
19. Moorhead PS, Nowell PC, Mellman WJ, Battipps DM and Hungerford DA (1960) Chromosome preparation of leukocytes cultured from peripheral blood. Exp Cell Res 20:613-616.
20. Natarajan AT, Balajee AS, Boei JJ, Darroudi F, Dominguez I, Hande MP, Meijers M, Stijepcevic P, Vermeulen S and Xiao Y (1996) Mechanisms of induction of chromosomal aberrations and their detection by in situ hybridization. Mutat Res 372:247-58.
21. Perry PE and Wolff S (1974) New Giemsa method for differential staining of sister chromatids. Nature 251:156-158.
22. Plunkett W, Chubb S, Alexander L and Montgomery JA (1980) Comparison of the toxicity and metabolism of 9-β-D-arabinofuranosyl-2-fluoroadenine and 9-β-D-arabinofuranosyladenine in human lymphoblastoid cells. Cancer Res 40:2349-55.
23. Pott-Hoeck C and Hiddemann W (1995) Purine analogs in the treatment of low-grade lymphomas and chronic lymphocytic leukemias. Ann Oncol 8:421-433.
24. Preston RJ, Dean BJ, Galloway S, Holden H, McFee AF and Shelby M (1987) Mammalian in vivo cytogenetic assays. Analysis of chromosome aberrations in bone marrow cells. Mutat Res 189:157-65.
25. Robak T (2001) Cladribine in the treatment of chronic lymphocytic leukemia. Leuk Lymphoma 40:551-564.
26. Robak T, Góra-Tybor J, Urbanska H and Krikowski E (1999) Combination regimen of 2-chlorodeoxyadenosine (cladribine), mitoxantrone and dexamethasone (CMD) in treatment of refractory and recurrent low-grade non-Hodgkin lymphoma. Leuk Lympho 32:359-363.
27. Robertsson LE, Chubb S, Meyn RE, Story M, Ford R, Hitelman WN and Plunkett W (1993) Induction of apoptosis cell death in chronic lymphocytic leukemia by 2-chloro-2'-deoxyadenosine and 9-β-D-arabinosyl-2-fluoradenine. Blood 81:143-150.
28. Schrimer M, Mur E, Pfeiffer KP, Thaler J and Konwalinka G (1997) The safety profile of low-dose cladribine in refractory rheumatoid arthritis. A pilot trial. Scand J Rhematol 26:376-379.
29. Sidorova JM and Breeden LL (2003) Precocious G1/S transitions and genomic instability: The origin connection. Mutat Res 532:5-19.
30. Smorenburg CH, Sparreboom A, Bontenbal M and Verweij J (2001) Combination chemotherapy of the taxanes and antimetabolites: Its use and limitations. Eur J Cancer 37:2310-23.
31. Szafraniec SI, Stachnik KJ and Skierski JS (2004) New nucleoside analogs in the treatment of hematological disorders. Acta Pol Pharm 61:223-32.
32. Tallman MS, Hakimian D, Hogan D and Petersen L (1993) 2-Chlorodeoxyadenosine in the treatment of hairy cell leukemia (HCL): Detection of minimal residual disease (MRD) by immunostaining (IS). Presented at the 8th Symposium on the Molecular Biology of Hematopoiesis in Basel, July 9-13.
33. Tallman MS, Hakimian D, Variakojis D, Koslow D, Sisney GA Rademaker AW, Rose E and Kaul K (1992) A single cycle of 2-chlorodeoxyadenosine results in complete remission in the majority of patients with the hairy cell leukemia. Blood 80:2203-2209.
34. Traganos F, Staiano-Coico L, Darzynkiewicz Z and Melamed MR (1980) Effects of ellipticine on cell survival and cell cycle progression in cultured mammalian cells. Cancer Res 40:2390-2399.
35. Zwaan MC, Kaspers GJL. Pieters R, Hählen K, Huismans DR, Zimmermann M, Harbott J, Slater RM, Creutzig U and Veerman AJP (2002) Cellular drug resistance in childhood acute myeloid leukemia is related to chromosomal abnormalities. Blood 100:3352-3360.